HyperArc Registry Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 968
- 试验地点
- 7
- 主要终点
- Survival
研究概览
简要总结
The HyperArc registry is designed to collect data from which the efficacy of the HyperArc procedure can be assessed and compared to alternative treatments.
详细描述
A significant percentage of newly diagnosed cancer patients will develop brain metastases. For many of these patients, stereotactic radiosurgery (SRS) is recommended as a primary treatment option. Concerns about complexity, patient safety, cost, and human resources can make SRS challenging. HyperArc radiotherapy addresses these challenges by introducing key technology and workflow elements to streamline multi-leaf collimator-based, non-coplanar SRS. HyperArc is designed to deliver SRS treatments from the TrueBeam linear accelerator platform. The HyperArc registry is designed to collect data from which the efficacy of the HyperArc procedure can be assessed and compared to alternative treatments.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Received or scheduled to receive treatment using the HyperArc treatment method
- •Age of legal adult according to local law
- •Signed informed consent form, or, informed consent waived by the local ethics board/institutional review board
排除标准
- •None, apart from not meeting Inclusion Criteria
结局指标
主要结局
Survival
时间窗: follow until death, on average approximately 2 years
Survival
次要结局
- Local tumor control(follow until death, on average approximately 2 years)
- HyperArc Patterns of Care(Limited to course of treatment: up to 4 weeks)